Inventor · disambiguated record
Michael John Costanzo
Also filed as: COSTANZO MICHAEL J · COSTANZO MICHAEL JOHN
27 granted patents·11 pending applications·551 citations·filing 1992–2023
95Inventor score
Files withBETA PHARMA INC17ORTHO MCNEIL PHARM INC6COSTANZO MICHAEL J4ORTHO PHARMA CORP3JANSSEN PHARMACEUTICA NV2
Top patents by PatentIndex Score
38 records- 0194US5384327AAnticonvulsant sorbopyranose sulfamatesMCNEILAB INC·Filed 1992·Granted Jan 24, 1995·118 cites·9 claims
- 0294US5242942AAnticonvulsant fructopyranose cyclic sulfites and sulfatesMCNEILAB INC·Filed 1992·Granted Sep 7, 1993·117 cites·29 claims
- 0391US6323219B1Methods for treating immunomediated inflammatory disordersORTHO MCNEIL PHARM INC·Filed 1999·Granted Nov 27, 2001·135 cites·21 claims
- 0488US5523308APeptidyl heterocycles useful in the treatment of thrombin related disordersFiled 1995·Granted Jun 4, 1996·94 cites·40 claims
- 0587US9878994B22-H-indazole derivatives as cyclin-dependent kinase (CDK) inhibitors and therapeutic uses thereofBETA PHARMA INC·Filed 2015·Granted Jan 30, 2018·8 cites·32 claims
- 0685US10239864B22-H-indazole derivatives as cyclin-dependent kinase (CDK) inhibitors and therapeutic uses thereofBETA PHARMA INC·Filed 2018·Granted Mar 26, 2019·5 cites·20 claims
- 0784US6469036B1Peptidyl heterocyclic ketones useful as tryptase inhibitorsORTHO MCNEIL PHARM INC·Filed 2000·Granted Oct 22, 2002·23 cites·24 claims
- 0876US10590111B2Substituted 2-anilinopyrimidine derivatives as EGFR modulatorsBETA PHARMA INC·Filed 2015·Granted Mar 17, 2020·2 cites·39 claims
- 0976US5827866APeptidyl heterocycles useful in the treatment of thrombin related disordersORTHO PHARMA CORP·Filed 1995·Granted Oct 27, 1998·21 cites·19 claims
- 1071US8158792B2Spiropiperidines for use as tryptase inhibitorsCOSTANZO MICHAEL J·Filed 2008·Granted Apr 17, 2012·2 cites·8 claims
- 1169US12187707B2Pharmaceutical formulations of N-(2-(2-(dimethylamino)ethoxy)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylaminde and salts thereofBETA PHARMA INC·Filed 2021·Granted Jan 7, 2025·0 cites·13 claims
- 1269US7825110B2Substituted spiroheterocyclesJANSSEN PHARMACEUTICA NV·Filed 2007·Granted Nov 2, 2010·1 cites·25 claims
- 1365US11180478B2Pharmaceutical formulations of N-(2-(2-(dimethylamino) ethoxy)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide and salts thereofBETA PHARMA INC·Filed 2018·Granted Nov 23, 2021·0 cites·15 claims
- 1463US5827860APeptidyl heterocycles useful in the treatment of thrombin related disordersORTHO PHARMA CORP·Filed 1995·Granted Oct 27, 1998·10 cites·17 claims
- 1561US11414401B2Substituted 2-anilinopyrimidine derivatives as EGFR modulatorsBETA PHARMA INC·Filed 2020·Granted Aug 16, 2022·0 cites·7 claims
- 1660US2025276968A18- and 6-substituted pyridopyrimidine derivatives as kras inhibitorsBETA PHARMA INC·Filed 2023·Application pending·0 cites
- 1759US10844045B2Pharmaceutical salts N-(2-(2-(dimethylamino)ethoxy)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide and crystalline forms thereofBETA PHARMA INC·Filed 2017·Granted Nov 24, 2020·0 cites·23 claims
- 1858US6069254ACarboxamide derivatives of piperidine for the treatment of thrombosis disordersORTHO PHARMA CORP·Filed 1997·Granted May 30, 2000·14 cites·2 claims
- 1958US2025250286A1Fused pyrimidine derivatives as kras oncoprotein inhibitorsBETA PHARMA INC·Filed 2022·Application pending·0 cites
- 2056US11052086B22-anilinopyrimidine derivatives as therapeutic agents for treatment of brain cancersBETA PHARMA INC·Filed 2017·Granted Jul 6, 2021·0 cites·7 claims
- 2156US7132418B2Peptidyl heterocyclic ketones useful as tryptase inhibitorsORTHO MCNEIL PHARM INC·Filed 2002·Granted Nov 7, 2006·1 cites·17 claims
- 2254US11352341B22H-indazole derivatives as CDK4 and CDK6 inhibitors and therapeutic uses thereofBETA PHARMA INC·Filed 2019·Granted Jun 7, 2022·0 cites·19 claims
- 2354US2024140948A1Pyridopyrimidine derivatives as kras inhibitorsBETA PHARMA INC·Filed 2022·Application pending·0 cites
- 2453US12258365B2Organophosphorus-substituted compounds as c-MET inhibitors and therapeutic uses thereofBETA PHARMA INC·Filed 2019·Granted Mar 25, 2025·0 cites·30 claims
- 2552US2023099858A1Pyridopyrimidine derivatives as kras inhibitorsBETA PHARMA INC·Filed 2021·Application pending·0 cites
- 2651US2024002365A1Pyridazine and 1,2,4-triazine derivatives as fgfr kinase inhibitorsBETA PHARMA INC·Filed 2021·Application pending·0 cites
- 2750US12390464B2Treatment of EGFR mutant-related cancers using a combination of EGFR and CDK4/6 inhibitorsBETA PHARMA INC·Filed 2020·Granted Aug 19, 2025·0 cites·20 claims
- 2847US7825111B2Substituted spiroheterocyclesJANSSEN PHARMACEUTICA NV·Filed 2007·Granted Nov 2, 2010·0 cites·26 claims
- 2946US2022079944A12h-indazole derivatives as therapeutic agents for brain cancers and brain metastasesBETA PHARMA INC·Filed 2020·Application pending·0 cites
- 3046US2011082306A1Birch reduction of steroid substrates via alkali metal - silica gel materialsCOSTANZO MICHAEL J·Filed 2009·Application pending·0 cites
- 3145US8536189B2Spiropiperidines for use as tryptase inhibitorsCOSTANZO MICHAEL J·Filed 2012·Granted Sep 17, 2013·0 cites·3 claims
- 3245US2008306044A1Spirobenzoazepanes as vasopressin antagonistsCOSTANZO MICHAEL J·Filed 2008·Application pending·0 cites
- 3344US7718673B2Isonipecotamides for the treatment of integrin-mediated disordersORTHO MCNEIL PHARM INC·Filed 2003·Granted May 18, 2010·0 cites·17 claims
- 3442US2014308317A1Polymeric Compounds And Methods Of Making And Using The SameFAN XIAODONG·Filed 2013·Application pending·0 cites
- 3541US7081460B2Quinazoline and quinazoline-like compounds for the treatment of integrin-mediated disordersORTHO MCNEIL PHARM INC·Filed 2002·Granted Jul 25, 2006·0 cites·45 claims
- 3640US6495523B1Tricyclic monosaccharide derivatives useful in treating acute ischemia-induced neurodegenerationORTHO MCNEIL PHARM INC·Filed 2000·Granted Dec 17, 2002·0 cites·25 claims
- 3740US2015094294A1Compounds and methods for treating malariaCELLCEUTIX CORP·Filed 2013·Application pending·0 cites
- 3835US2011178104A1Anti-Heparin CompoundsPOLYMEDIX INC·Filed 2011·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →